纖維肌痛藥物市場規模、佔有率及成長分析（依藥物類別、診斷方法、給藥途徑、藥物類型、治療通路、通路、最終用戶及地區）－2025-2032 年產業預測

2023 年全球纖維肌痛藥物市場規模價值 35 億美元，預計將從 2024 年的 37.9 億美元成長到 2032 年的 71.1 億美元，預測期內（2025-2032 年）的複合年成長率為 8.2%。

纖維肌痛症是一種慢性疼痛疾病，影響全球約 2% 的成年人，表現為廣泛的疼痛、疲勞以及睡眠障礙和認知障礙等其他症狀，女性的盛行率明顯更高。雖然沒有治療方法，但有各種治療策略來改善症狀管理並提高患者的生活品質。這些治療策略整合了藥物治療、生活方式改變和非藥物治療，旨在緩解疼痛、改善睡眠品質和解決認知問題。纖維肌痛的複雜性需要採用多學科治療方法，通常根據每個人的獨特需求進行客製化，突出了個人化治療對於有效管理這種多方面疾病的重要性。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局

纖維肌痛治療市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概覽
• 抗憂鬱症
• 抗驚厥藥
• 肌肉鬆弛劑
• 其他

纖維肌痛治療市場規模（依診斷方法及複合年成長率）（2025-2032）

• 市場概覽
• 血液檢查
• 身體檢查

纖維肌痛治療市場規模（按給藥途徑和複合年成長率） (2025-2032)

• 市場概覽
• 口服
• 注射劑
• 局部的

纖維肌痛治療藥物市場規模（依藥物類型及複合年成長率）（2025-2032）

• 市場概覽
• 品牌
• 非專利的

纖維肌痛治療市場規模（依治療管道及複合年成長率） (2025-2032)

• 市場概覽
• 醫院
• 診所
• 居家照護

纖維肌痛治療藥物市場規模（依分銷管道分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院藥房
• 零售藥局
• 網路藥局

纖維肌痛治療藥物市場規模（按最終用戶和複合年成長率分類）（2025-2032）

• 市場概覽
• 成人
• 孩子們

纖維肌痛治療藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Pfizer Inc.（USA）
• AbbVie Inc.（USA）
• Eli Lilly and Company（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GlaxoSmithKline plc（UK）
• Aptinyx Inc.（USA）
• Tonix Pharmaceuticals Holding Corp.（USA）
• Virios Therapeutics（USA）
• Astellas Pharma Inc.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Boehringer Ingelheim GmbH（Germany）
• Novartis AG（Switzerland）
• Johnson & Johnson（USA）
• Merck & Co., Inc.（USA）
• Bristol-Myers Squibb Company（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Sun Pharmaceutical Industries Ltd.（India）
• Mylan NV（USA）
• Lupin Limited（India）

結論和建議

Global Fibromyalgia Treatment Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 3.79 billion in 2024 to USD 7.11 billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

Fibromyalgia, a chronic pain disorder that affects approximately 2% of adults globally, manifests through widespread pain, fatigue, and additional symptoms like sleep disturbances and cognitive difficulties, with a notably higher prevalence in women. Although there is no cure, various treatment strategies exist to improve symptom management and enhance the quality of life for those affected. These strategies integrate medications, lifestyle changes, and non-pharmacological therapies, aiming to alleviate pain, improve sleep quality, and tackle cognitive issues. The complexity of fibromyalgia necessitates a multidisciplinary treatment approach, often customized to meet the unique needs of each individual, highlighting the importance of personalized care in effectively managing this multifaceted condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Fibromyalgia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Fibromyalgia Treatment Market Segments Analysis

Global Fibromyalgia Treatment Market is segmented by Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User and region. Based on Drug Class, the market is segmented into Antidepressants, Antiepileptics, Muscle Relaxants and Others. Based on Diagnosis Method, the market is segmented into Blood Tests and Physical Examination. Based on Route of Administration, the market is segmented into Oral, Injectable and Topical. Based on Drug Type, the market is segmented into Branded and Generic. Based on Treatment Channel, the market is segmented into Hospitals, Clinics and Homecare. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on End User, the market is segmented into Adults and Pediatrics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Fibromyalgia Treatment Market

The global fibromyalgia treatment market is primarily driven by the rising incidence of fibromyalgia across the globe. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) estimates that around five million adults in the United States are affected by this condition, with a staggering 80 to 90 percent of patients being women. This gender disparity highlights the significant toll fibromyalgia takes on women. As awareness surrounding the condition grows and diagnostic methods advance, more cases are being identified globally. Additionally, the limited number of specifically approved medications, currently just three, has led to increased dependence on off-label and generic treatments, further influencing market dynamics. The expiration of patent protections for Lyrica in June 2019 has also introduced generic alternatives, intensifying competition and impacting overall market growth.

Restraints in the Global Fibromyalgia Treatment Market

The Global Fibromyalgia Treatment market faces notable restraints due to the limited number of drugs specifically approved for this condition, currently standing at only three options. This scarcity leads to a greater reliance on off-label medications and generic antidepressants to manage symptoms. Moreover, the expiration of patent protection for Lyrica, a crucial medication for fibromyalgia treatment, in June 2019 has significantly impacted market revenues. The introduction of generic alternatives has intensified competition, which further constrains overall market growth. These factors collectively hinder advancements and limit treatment options available to individuals suffering from fibromyalgia worldwide.

Market Trends of the Global Fibromyalgia Treatment Market

The Global Fibromyalgia Treatment market is witnessing a notable trend toward the introduction of innovative therapies, driven by key industry players aiming to enhance their presence. The anticipated launch and approval of novel treatments, such as Galcanezumab by Eli Lilly and Company, highlights a strategic focus on expanding existing drug indications to better address the multifaceted needs of fibromyalgia patients. With Galcanezumab currently undergoing clinical trials for fibromyalgia, its upcoming results may significantly impact market dynamics. This proactive engagement in research and development underscores a growing commitment within the pharmaceutical sector to develop effective solutions, thereby contributing to robust market growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Fibromyalgia Treatment Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antidepressants
• Antiepileptics
• Muscle Relaxants
• Others

Global Fibromyalgia Treatment Market Size by Diagnosis Method & CAGR (2025-2032)

• Market Overview
• Blood Tests
• Physical Examination

Global Fibromyalgia Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Topical

Global Fibromyalgia Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generic

Global Fibromyalgia Treatment Market Size by Treatment Channel & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Homecare

Global Fibromyalgia Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Fibromyalgia Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Adults
• Pediatrics

Global Fibromyalgia Treatment Market Size & CAGR (2025-2032)

• North America (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • US
  • Canada
• Europe (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Diagnosis Method, Route of Administration, Drug Type, Treatment Channel, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptinyx Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonix Pharmaceuticals Holding Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virios Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations